I am a healthcare professional


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.


I am a healthcare professional
(outside the UK and Australia):

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Macula Society

Macula Society 2022

Coming soon
04:28 PM
Duration 9mins Main Room
Development of a short form of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25)
Singerman L, Tschosik E, Doll H, Drawnel F, Singerman B, Gentile B
04:46 PM
Duration 9mins Main Room
Faricimab in Neovascular Age-Related Macular Degeneration: Efficacy, Safety, and Durability Through Week 48 in the Phase 3 TENAYA and LUCERNE Trials
Priglinger S, Margaron P, Demetriades AM, Silverman D, Ives J, Basu K, Lin H
04:55 PM
Duration 6mins Main Room
End-of-Study Results From the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) in Neovascular Age-Related Macular Degeneration (nAMD)
Kim J, Brooks L, Mittra R, Wykoff C, Callaway N, DeGraaf S, Fung AE, Gune S, LePogam S, Smith R, Willis J, Barteselli G
05:01 PM
Duration 6mins Main Room
Long-term Safety and Efficacy of the Port Delivery System With Ranibizumab (PDS) in Neovascular Age-Related Macular Degeneration (nAMD): Interim Analysis of the Portal Extension Trial
Dhoot D, Callaway N, DeGraaf S, Barteselli G, Gune S, LePogam S, Rabena M, Smith R
08:52 AM
Duration 6mins Main Room
Personalized Treatment Interval (PTI) Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
Chakravarthy U, Baumal CR, Kitchens JW, Jaffe GJ, Gerendas BS, Abreu F, Camino A, Jain N, Haskova Z, Tang Y
09:30 AM
Duration 9mins Main Room
Prevalence, Incidence, and Progression of Macular Atrophy (MA) in Eyes With Neovascular Age-Related Macular Degeneration (nAMD) Over 96 Weeks in the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS)
Jaffe G, Gune S, Cameron B, Barteselli G, Callway N
08:26 AM
Duration 6mins Main Room
Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Baumal CR, Wells JA, Danzig CJ, Eichenbaum DA, Lim JI, Haskova Z, Mohan S, Silverman D, Tang Y, Lin H